Literature DB >> 10898694

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group.

S L Letendre1, E V Capparelli, R J Ellis, J A McCutchan.   

Abstract

Plasma and cerebrospinal fluid (CSF) indinavir concentrations were measured by high-performance liquid chromatography. The median concentration in plasma exceeded that in CSF 10-fold. The modeled CSF curve was flat at 155 nM, and the estimated ratio of the areas under the CSF and plasma concentration-time curves was 6%. We conclude that CSF indinavir concentrations are lower than levels in plasma but exceed the clinical 95% inhibitory concentration range.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10898694      PMCID： PMC90032          DOI： 10.1128/AAC.44.8.2173-2175.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

Authors:  S Kravcik; K Gallicano; V Roth; S Cassol; N Hawley-Foss; A Badley; D W Cameron
Journal:  J Acquir Immune Defic Syndr       Date:  1999-08-15       Impact factor: 3.731

2.  Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir.

Authors:  G Pialoux; S Fournier; A Moulignier; J D Poveda; F Clavel; B Dupont
Journal:  AIDS       Date:  1997-08       Impact factor: 4.177

3.  A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

Authors:  D S Stein; D G Fish; J A Bilello; S L Preston; G L Martineau; G L Drusano
Journal:  AIDS       Date:  1996-05       Impact factor: 4.177

4.  Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man.

Authors:  R Nau; G Zysk; A Thiel; H W Prange
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Penetration of newer cephalosporins into cerebrospinal fluid.

Authors:  C E Cherubin; R H Eng; R Norrby; J Modai; G Humbert; G Overturf
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

6.  Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group.

Authors:  R J Ellis; K Hsia; S A Spector; J A Nelson; R K Heaton; M R Wallace; I Abramson; J H Atkinson; I Grant; J A McCutchan
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

7.  Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain.

Authors:  J C McArthur; D R McClernon; M F Cronin; T E Nance-Sproson; A J Saah; M St Clair; E R Lanier
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

Review 8.  Antibiotic pharmacodynamics in cerebrospinal fluid.

Authors:  I Lutsar; G H McCracken; I R Friedland
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

9.  Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.

Authors:  B U Mueller; L L Lewis; G J Yuen; M Farley; A Keller; J A Church; J C Goldsmith; D J Venzon; M Rubin; P A Pizzo; F M Balis
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.

Authors:  F Aweeka; A Jayewardene; S Staprans; S E Bellibas; B Kearney; P Lizak; T Novakovic-Agopian; R W Price
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-01-01
View more
  29 in total

1.  Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.

Authors:  G L Drusano; S L Preston; M H Gotfried; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 2.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

Review 3.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

4.  Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.

Authors:  Bregt S Kappelhoff; Alwin D R Huitema; Sanjay U C Sankatsing; Pieter L Meenhorst; Eric C M Van Gorp; Jan W Mulder; Jan M Prins; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

5.  Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

Authors:  David Croteau; Scott Letendre; Brookie M Best; Ronald J Ellis; Sheila Breidinger; David Clifford; Ann Collier; Benjamin Gelman; Christina Marra; Gilbert Mbeo; Allen McCutchan; Susan Morgello; David Simpson; Lauren Way; Florin Vaida; Susan Ueland; Edmund Capparelli; Igor Grant
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

6.  Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS.

Authors:  Susanne May; Scott Letendre; Richard Haubrich; J Allen McCutchan; Robert Heaton; Edmund Capparelli; Ronald Ellis
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-10       Impact factor: 4.147

7.  Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.

Authors:  Eric H Decloedt; Bernd Rosenkranz; Gary Maartens; John Joska
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

8.  Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.

Authors:  M C Strain; S Letendre; S K Pillai; T Russell; C C Ignacio; H F Günthard; B Good; D M Smith; S M Wolinsky; M Furtado; J Marquie-Beck; J Durelle; I Grant; D D Richman; T Marcotte; J A McCutchan; R J Ellis; J K Wong
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

9.  Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Low atazanavir concentrations in cerebrospinal fluid.

Authors:  Brookie M Best; Scott L Letendre; Eileen Brigid; David B Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; David M Simpson; Ronald Ellis; Edmund V Capparelli; Igor Grant
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.